BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 27893709)

  • 1. Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer.
    Yu L; Liang Y; Cao X; Wang X; Gao H; Lin SY; Schiff R; Wang XS; Li K
    Oncogene; 2017 May; 36(20):2910-2918. PubMed ID: 27893709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
    Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
    Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
    [No Abstract]   [Full Text] [Related]  

  • 3. G9a-mediated methylation of ERα links the PHF20/MOF histone acetyltransferase complex to hormonal gene expression.
    Zhang X; Peng D; Xi Y; Yuan C; Sagum CA; Klein BJ; Tanaka K; Wen H; Kutateladze TG; Li W; Bedford MT; Shi X
    Nat Commun; 2016 Mar; 7():10810. PubMed ID: 26960573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SnoN oncoprotein enhances estrogen receptor-α transcriptional activity.
    Band AM; Laiho M
    Cell Signal; 2012 Apr; 24(4):922-30. PubMed ID: 22227247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.
    Kim SS; Lee MH; Lee MO
    Breast Cancer Res Treat; 2020 Feb; 180(1):45-54. PubMed ID: 31897900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Combinatorial Epigenetic Therapy Using Resveratrol and Pterostilbene for Restoring Estrogen Receptor-α (ERα) Expression in ERα-Negative Breast Cancer Cells.
    Kala R; Tollefsbol TO
    PLoS One; 2016; 11(5):e0155057. PubMed ID: 27159275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PELP1 oncogenic functions involve CARM1 regulation.
    Mann M; Cortez V; Vadlamudi R
    Carcinogenesis; 2013 Jul; 34(7):1468-75. PubMed ID: 23486015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide re-sensitizes ERα-negative breast cancer cells to endocrine therapy by restoring ERα expression in vitro and in vivo.
    Zhang W; Wang L; Fan Q; Wu X; Wang F; Wang R; Ma Z; Yang J; Lu SH
    Oncol Rep; 2011 Sep; 26(3):621-8. PubMed ID: 21687957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone acetyltransferase Hbo1 destabilizes estrogen receptor α by ubiquitination and modulates proliferation of breast cancers.
    Iizuka M; Susa T; Takahashi Y; Tamamori-Adachi M; Kajitani T; Okinaga H; Fukusato T; Okazaki T
    Cancer Sci; 2013 Dec; 104(12):1647-55. PubMed ID: 24125069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of histone methyltransferase DOT1L silences ERα gene and blocks proliferation of antiestrogen-resistant breast cancer cells.
    Nassa G; Salvati A; Tarallo R; Gigantino V; Alexandrova E; Memoli D; Sellitto A; Rizzo F; Malanga D; Mirante T; Morelli E; Nees M; Åkerfelt M; Kangaspeska S; Nyman TA; Milanesi L; Giurato G; Weisz A
    Sci Adv; 2019 Feb; 5(2):eaav5590. PubMed ID: 30775443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of estrogen receptor alpha-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy.
    Liu W; Ip MM; Podgorsak MB; Das GM
    Breast Cancer Res Treat; 2009 May; 115(1):43-50. PubMed ID: 18481172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrinsic ubiquitin E3 ligase activity of histone acetyltransferase Hbo1 for estrogen receptor α.
    Iizuka M; Susa T; Tamamori-Adachi M; Okinaga H; Okazaki T
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(7):498-510. PubMed ID: 28769019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells.
    Zhao C; Matthews J; Tujague M; Wan J; Ström A; Toresson G; Lam EW; Cheng G; Gustafsson JA; Dahlman-Wright K
    Cancer Res; 2007 Apr; 67(8):3955-62. PubMed ID: 17440111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
    Chang J; Sui M; Fan W
    Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer.
    Tokuda E; Seino Y; Arakawa A; Saito M; Kasumi F; Hayashi S; Yamaguchi Y
    Breast Cancer Res Treat; 2012 Jun; 133(2):427-36. PubMed ID: 21909982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage.
    Yu S; Gong X; Ma Z; Zhang M; Huang L; Zhang J; Zhao S; Zhu T; Yu Z; Chen L
    Cell Oncol (Dordr); 2020 Feb; 43(1):65-80. PubMed ID: 31701491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-497 downregulation contributes to cell proliferation, migration, and invasion of estrogen receptor alpha negative breast cancer by targeting estrogen-related receptor alpha.
    Han L; Liu B; Jiang L; Liu J; Han S
    Tumour Biol; 2016 Oct; 37(10):13205-13214. PubMed ID: 27456360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.